OS20 Online 15 December

1. 1EuFMD | Open Session special edition | #OS20se
Vaccine Banks
A unique solution to address emergency
needs for quality vaccine
Pascal Hudelet
The VPH Center of

2. 2
FMD vaccines: no stocks are available
• Constant competition between regular, predictable demand
and sudden surges due to
• Outbreaks in free or endemic countries
• Unexpected funding availability
• There is no idle manufacturing capacity ready to serve an
increase in demand
• Sales forecasts are often unreliable in a market mostly based on
tenders & orders with unrealistic delivery expectations
• Banks or Strategic reserves are the only available solution for
rapid access to vaccine from a supply perspective
60
80
100
120
140

3. 3
Banks: an acknowledged tool for disease-free countries
• Today the antigen bank model is mostly used by FMD-free countries
• Trend toward mutualization of efforts
• International Vaccine Bank
• European Union
• North American FMD Vaccine Bank
• QUADS
• Downsides
• Financial & QA considerations => valuable antigen stock is often destroyed at the end of the
storage period
• Policies and preparedness plans not always aligned with vaccination
• Preferred options often remain 1/Stamping out 2/Vaccinate to Kill

4. 4
Banks: a solution for endemic countries
• Banks can be used in endemic countries
• As a buffer stock to respond to sudden surges in demand
• As an insurance against introduction of exotic strains
• As trigger for pilot vaccination campaigns
• A regional approach is recommended - Regional banks funded by international
organizations:
• OIE SEACFMD bank
• OIE/WHO Rabies vaccine bank
• PAHO rabies
• Sustainable models should be invented
• Donor funding during first steps of PCP
• Provide support to put in place infrastructure needed for vaccination campaigns
• Perform economic analysis of benefits of vaccination
• Transfer to country ownership –once they realize vaccines are only a minor part of the cost of a
campaign

5. 5
Conclusions
• Antigen and vaccine banks are one of the solutions to reach vaccine
security
• Today they are mostly used as by disease-free countries, as an
insurance, part of their risk mitigation strategy to mimize the
devastating consequences of outbreaks
• But they could also help minimize vaccine shortages in endemic
countries
• They may seem costly to put in place but guarantee access to quality
vaccine when needed